Dysregulation of PAX5 causes uncommitted B cell development and tumorigenesis in mice

Autor: Cho, Helian K, Barthel N, Adria Closa, Hannes Bergmann, Carla M. Roots, Lisa A. Miosge, Eduardo Eyras, Joanne H. Reed, Ian A. Cockburn, Mehmet Yabas, Brigette Boast, Xi Li, Stephen L. Nutt, Anselm Enders, Henry J. Sutton, Omari Sa, Christopher C. Goodnow, Nadine Hein, Young C, T. Andrews, Katherine M. Hannan

PAX5 is the master transcription factor controlling B cell identity. In humans, mutations in PAX5 account for 30% of B cell acute lymphoblastic leukemia (B-ALL) cases. Investigating the causal effects of PAX5 mutations has however been difficult due

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30e0d81ba5b13e24470b345a4f1ce286
https://doi.org/10.1101/2021.01.29.428877

Direct Z-scheme heterojunction impregnated MoS 2 -NiO-CuO nanohybrid for efficient photocatalyst and dye-sensitized solar cell.

Autor: Dharmalingam K; Smart Energy Materials Research Laboratory, Department of Energy Science and Technology, Periyar University, Salem, India., Bojarajan AK; Department of Mechanical and Aerospace Engineering, United Arab Emirates University, Al Ain, 15551, UAE.; National Water and Energy Center, United Arab Emirates University, Al Ain, 15551, UAE., Gopal R; Quantum Materials Research Lab (QMRL), Department of Nanoscience and Technology, Alagappa University, Karaikudi, India., Thangavel E; Smart Energy Materials Research Laboratory, Department of Energy Science and Technology, Periyar University, Salem, India. elangoes@periyaruniversity.ac.in., Burhan Al Omari SA; Department of Mechanical and Aerospace Engineering, United Arab Emirates University, Al Ain, 15551, UAE., Sangaraju S; National Water and Energy Center, United Arab Emirates University, Al Ain, 15551, UAE. s_sambasivam@uaeu.ac.ae.

Publikováno v: Scientific reports [Sci Rep] 2024 Jun 24; Vol. 14 (1), pp. 14518. Date of Electronic Publication: 2024 Jun 24.

Optimized flow cytometric detection of transient receptor potential vanilloid-1 (TRPV1) in human hematological malignancies.

Autor: Omari SA; School of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia. somari@ccia.org.au.; Children's Cancer Institute, School of Women's and Children's Health, Lowy Cancer Centre, University of New South Wales (UNSW), Sydney, NSW, Australia. somari@ccia.org.au., Geraghty DP; School of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia.; Academic Division, University of Tasmania, Locked Bag 1351, Launceston, TAS, 7250, Australia., Khalafallah AA; School of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia.; Launceston General Hospital, Charles Street, Launceston, TAS, 7250, Australia., Venkat P; Children's Cancer Institute, School of Women's and Children's Health, Lowy Cancer Centre, University of New South Wales (UNSW), Sydney, NSW, Australia., Shegog YM; School of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia., Ragg SJ; Pathology Department, Royal Hobart Hospital, 48 Liverpool Street, Hobart, TAS, 7000, Australia., de Bock CE; Children's Cancer Institute, School of Women's and Children's Health, Lowy Cancer Centre, University of New South Wales (UNSW), Sydney, NSW, Australia., Adams MJ; School of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, TAS, 7250, Australia.; College of Science, Health, Engineering & Education, Murdoch University, Perth, WA, 6150, Australia.

Publikováno v: Medical oncology (Northwood, London, England) [Med Oncol] 2022 Apr 28; Vol. 39 (5), pp. 81. Date of Electronic Publication: 2022 Apr 28.

A Point Mutation in IKAROS ZF1 Causes a B Cell Deficiency in Mice.

Autor: Boast B; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Miosge LA; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Kuehn HS; Immunology Service, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20892., Cho V; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Athanasopoulos V; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia.; Centre for Personalised Immunology, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., McNamara HA; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Sontani Y; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Mei Y; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Howard D; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Sutton HJ; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Omari SA; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia.; Children's Cancer Institute, School of Women's and Children's Health, Lowy Cancer Centre, University of New South Wales, Sydney, New South Wales 2031, Australia., Yu Z; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Nasreen M; Australian Phenomics Facility, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia; and., Andrews TD; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Cockburn IA; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia., Goodnow CC; Immunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia., Rosenzweig SD; Immunology Service, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20892., Enders A; Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia; anselm.enders@anu.edu.au.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2021 Apr 01; Vol. 206 (7), pp. 1505-1514. Date of Electronic Publication: 2021 Mar 03.

TRPV1 Channels in Immune Cells and Hematological Malignancies.

Autor: Omari SA; School of Health Sciences, University of Tasmania, Launceston, TAS, Australia., Adams MJ; School of Health Sciences, University of Tasmania, Launceston, TAS, Australia., Geraghty DP; School of Health Sciences, University of Tasmania, Launceston, TAS, Australia. Electronic address: d.geraghty@utas.edu.au.

Publikováno v: Advances in pharmacology (San Diego, Calif.) [Adv Pharmacol] 2017; Vol. 79, pp. 173-198. Date of Electronic Publication: 2017 Mar 21.